Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $542,300.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of Akero Therapeutics stock in a transaction on Monday, June 16th. The shares were sold at an average price of $54.23, for a total value of $542,300.00. Following the completion of the sale, the insider now directly owns 92,231 shares of the company's stock, valued at $5,001,687.13. The trade was a 9.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, June 18th, Catriona Yale sold 1,633 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.84, for a total value of $89,553.72.
• On Tuesday, June 10th, Catriona Yale sold 2,803 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $151,362.00.
• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $39.30, for a total transaction of $393,000.00.
• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The stock was sold at an average price of $37.91, for a total value of $343,957.43.

Akero Therapeutics Stock Down 0.3%

NASDAQ:AKRO traded down $0.17 during midday trading on Monday, hitting $54.03. 1,271,779 shares of the company were exchanged, compared to its average volume of 1,014,119. Akero Therapeutics, Inc. has a fifty-two week low of $21.02 and a fifty-two week high of $58.40. The company has a market capitalization of $4.31 billion, a PE ratio of -27.71 and a beta of -0.16. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $45.88 and a 200 day simple moving average of $41.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. As a group, equities analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

A number of institutional investors have recently modified their holdings of AKRO. RTW Investments LP boosted its stake in shares of Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after buying an additional 940,388 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Akero Therapeutics by 11.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company's stock valued at $194,997,000 after purchasing an additional 495,119 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Akero Therapeutics by 14.2% in the first quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company's stock valued at $171,256,000 after purchasing an additional 526,233 shares during the period. Deep Track Capital LP raised its stake in shares of Akero Therapeutics by 116.0% during the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after purchasing an additional 800,216 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Akero Therapeutics by 93.3% during the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock worth $46,786,000 after purchasing an additional 557,794 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on AKRO shares. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Bank of America boosted their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Citigroup reduced their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, HC Wainwright boosted their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.